# Arcus Biosciences

> biopharmaceutical company

**Wikidata**: [Q113503877](https://www.wikidata.org/wiki/Q113503877)  
**Source**: https://4ort.xyz/entity/arcus-biosciences

## Summary
Arcus Biosciences is a biopharmaceutical company founded in 2015 that specializes in precision medicine, immuno-oncology, and immunotherapy. Headquartered in Hayward, California, the organization operates as a public company listed on the New York Stock Exchange under the ticker symbol RCUS.

## Key Facts
- **Founded:** 2015
- **Headquarters:** Hayward
- **Industry:** Pharmaceutical industry
- **Classification:** Public company (offers securities for sale to the general public)
- **Stock Exchange:** New York Stock Exchange (Ticker: RCUS)
- **Listing Date:** March 15, 2018
- **Fields of Work:** Precision medicine, immuno-oncology, immunotherapy
- **Legal Name:** Arcus Biosciences, Inc.
- **Central Index Key (CIK):** 0001724521
- **Ringgold ID:** 474085
- **Crunchbase ID:** arcus-biosciences
- **Website:** https://arcusbio.com/

## FAQs
**What is Arcus Biosciences?**
Arcus Biosciences is a biopharmaceutical company focused on the development of cancer therapies, specifically within the fields of precision medicine, immuno-oncology, and immunotherapy.

**Is Arcus Biosciences a public company?**
Yes, Arcus Biosciences is a publicly traded company. It offers its securities for sale to the general public and is listed on the New York Stock Exchange.

**When did Arcus Biosciences go public?**
The company began trading on the New York Stock Exchange on March 15, 2018, under the ticker symbol RCUS.

**Where is Arcus Biosciences located?**
The company is headquartered in Hayward.

**What are the key areas of research for Arcus Biosciences?**
The company concentrates its work on precision medicine, immuno-oncology, and immunotherapy, aiming to advance treatments in the pharmaceutical industry.

## Why It Matters
Arcus Biosciences plays a significant role in the biopharmaceutical sector by focusing on immuno-oncology and immunotherapy, which are critical areas for developing effective cancer treatments. As a public company, it provides a mechanism for public investment in medical innovation, specifically in the niche of precision medicine. Its status as a publicly held entity ensures strict adherence to regulatory disclosure standards, promoting transparency in its clinical and financial operations.

## Notable For
- Being listed on the New York Stock Exchange under the symbol RCUS since March 2018.
- Specializing in the high-precision fields of immuno-oncology and immunotherapy.
- Operating as a distinct joint-stock company with shares traded openly on a public market.

## Body

### Corporate Classification and Identity
Arcus Biosciences is legally recognized as a public company, meaning it is a corporation that offers its securities, such as stock, for sale to the general public. This structure distinguishes it from private companies by allowing its ownership to be distributed among public shareholders who trade shares on a market. It is also known by its full corporate alias, Arcus Biosciences, Inc. The company is a specific type of joint-stock organization and is distinctly classified as an enterprise within the pharmaceutical industry.

### Founding and Location
The company was established in 2015 with its headquarters based in Hayward. Since its inception, it has operated within the pharmaceutical sector, growing from a private entity into a publicly traded organization.

### Medical Focus and Industry
Arcus Biosciences operates within the pharmaceutical industry with a dedicated focus on three primary fields of work: precision medicine, immuno-oncology, and immunotherapy. These fields indicate the company's specialization in creating tailored medical treatments and leveraging the immune system to combat diseases, particularly cancer.

### Financial Market Presence
Arcus Biosciences is listed on the New York Stock Exchange (NYSE), a major global financial market. The company's stock trades under the ticker symbol RCUS. It officially joined the public market on March 15, 2018, marking the transition of its ownership to public shareholders. This listing requires the company to maintain strict regulatory disclosure and reporting standards to ensure transparency for investors.

### Identifiers and Digital Footprint
The organization is tracked by several key identifiers used in financial and academic databases. Its Central Index Key (CIK) is 0001724521, and it holds a Ringgold ID of 474085. In the startup and venture capital ecosystem, it is recognized by the Crunchbase organization ID "arcus-biosciences." The company maintains an official web presence at https://arcusbio.com/, which serves as its primary English-language digital interface.